Context: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG testing is used for serosurveillance and will be important to evaluate vaccination status. Given the urgency to release coronavirus disease 2019 (COVID-19) serology tests, most manufacturers have developed qualitative tests.
Objective: To evaluate clinical performance of six different SARS-CoV-2 IgG assays and their quantitative results to better elucidate the clinical role of serology testing in COVID-19.
Design: Six SARS-CoV-2 IgG assays were tested using remnant specimens from 190 patients. Sensitivity and specificity were evaluated for each assay with the current manufacturer's cutoff and a lower cutoff. A numeric result analysis and discrepancy analysis were performed
Results: The specificity was >93% for all assays, and sensitivity was >80% for all assays (≥ 7 days post-polymerase chain reaction [PCR] testing). Inpatients with more severe disease had higher numeric values compared to health care workers with mild or moderate disease. Several discrepant serology results were those just below the manufacturers cutoff.
Conclusions: SARS-CoV-2 IgG antibody testing can aid in the diagnosis of COVID-19 especially with negative PCR. Quantitative COVID-19 IgG results are important to better understand the immunological response and disease course of this novel virus and to assess immunity as part of future vaccination programs.
KC, JRL, ASF, MBP, and LMW are inventors on a patent application related to a COVID-19 diagnostic antibody test. KC is an inventor on a patent application related to a COVID-19 neutralization assay. Both applications are assigned to Albert Einstein College of Medicine. KC is a member of the scientific advisory board of Integrum Scientific, LLC. KC and JRL are members of the scientific advisory board of the Pandemic Security Initiative of Celdara Medical, LLC.
The other authors have no relevant financial interest in the products or companies described in this article (SKF, EPO, DYG, ASW, RHB, EL, CF, RJM, GIG, OV, YL, STC, JB, EMC, LRW).
Funding: R01-AI125462 to JRL; Einstein COVID Pilot Project grant to JRL and KC; RJM was supported by National Institute of Health (NIH) Medical Scientist Training Grant T32-GM007288 and Fellowship F30-AI150055; GIG was supported by NIH Training Program in Cellular and Molecular Biology and Genetics T32-GM007491.